Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence

References

• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–584.
   Google Scholar
• Chiorazzi A, Semperboni S, Marmiroli P. Current view in platinum drug mechanisms of peripheral neurotoxicity. Toxics. 2015;3(3):304–321.
   Google Scholar
• Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book. 2015;e553–60.
   Google Scholar
• Pike CT, Birnbaum HG, Muehlenbein CE, et al. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012;2012:913848.
   Google Scholar
• Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77.
   Google Scholar
• Argyriou AA, Kyritsis AP, Makatsoris T, et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135–147.
   Google Scholar
• Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27–46.
   Google Scholar
• Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract. 2011;2011:843019.
   Google Scholar
• Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(Suppl 4):iv45–54.
   Google Scholar
• Cavaletti G, Marmiroli P. Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. Expert Opin Pharmacother. 2018;19(2):113–121.
   Google Scholar
• Pachman DR, Barton DL, Swetz KM, et al. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30(30):3687–3696.
   Google Scholar
• Bennion AE, Molassiotis A. Qualitative research into the symptom experiences of adult cancer patients after treatments: a systematic review and meta-synthesis. Support Care Cancer. 2013;21(1):9–25.
   Google Scholar
• Pachman DR, Qin R, Seisler D, et al. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016;24(12):5059–5068.
   Google Scholar
• Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438–444.
   Google Scholar
• Argyriou AA, Polychronopoulos P, Iconomou G, et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34(4):368–377.
   Google Scholar
• Lucchetta M, Lonardi S, Bergamo F, et al. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol. 2012;70(6):899–902.
   Google Scholar
• Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. 2014;85(4):392–398.
   Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46(3):479–494.
   Google Scholar
• Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–781.
   Google Scholar
• Griffith KA, Dorsey SG, Renn CL, et al. Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. J Peripher Nerv Syst. 2014;19(2):127–135.
   Google Scholar
• Alberti P, Rossi E, Cornblath DR, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2014;25(1):257–264.
   Google Scholar
• Binda D, Vanhoutte EK, Cavaletti G, et al. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer. 2013;49(13):2910–2918.
   Google Scholar
• Cavaletti G, Cornblath DR, Merkies ISJ, et al. Patients’ and physicians’ interpretation of chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2019.
   Google Scholar
• Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst. 2011;16(3):228–236.
   Google Scholar
• Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006;11(2):135–141.
   Google Scholar
• Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61(9):1297–1300.
   Google Scholar
• Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53(8):1660–1664.
   Google Scholar
• Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013;24(2):454–462.
   Google Scholar
• Binda D, Cavaletti G, Cornblath DR, et al. group C-Ps. Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc(©)) in patients with chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst. 2015;20(3):328–332.
   Google Scholar
• Pachman DR, Qin R, Seisler DK, et al. Clinical Course of Oxaliplatin-Induced Neuropathy: results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416–3422.
   Google Scholar
• Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13(6):741–748.
   Google Scholar
• Huang HQ, Brady MF, Cella D, et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007;17(2):387–393.
   Google Scholar
• Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):1-11.
   Google Scholar
• Kerckhove N, Pereira B, Pezet D, et al. Clinical assessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint. Pain. 2017;158(1):180–182.
   Google Scholar
• Glimelius B, Manojlovic N, Pfeiffer P, et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx. Acta Oncol. 2018;57(3):393–402.
   Google Scholar
• Dorsey SG, Kleckner IR, Barton D, et al. NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst. 2019.
   Google Scholar
• Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018;91(9):403–413.
   Google Scholar
• Gewandter JS, Freeman R, Kitt RA, et al. Chemotherapy-induced peripheral neuropathy clinical trials: review and recommendations. Neurology. 2017;89(8):859–869.
   Google Scholar
• van de Poll-Franse LV, Horevoorts N, van Eenbergen M, et al. The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47(14):2188–2194.
   Google Scholar
• Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699–2707.
   Google Scholar
• Beijers AJ, Mols F, Tjan-Heijnen VC, et al. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol. 2015;54(4):463–469.
   Google Scholar
• Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205–2211.
   Google Scholar
• Rossen PB, Pedersen AF, Zachariae R, et al. Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol. 2009;27(35):5993–5999.
   Google Scholar
• Brouwers EE, Huitema AD, Boogerd W, et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol. 2009;48(6):832–841.
   Google Scholar
• Brydøy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101(24):1682–1695.
   Google Scholar
• Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011;16(5):708–716.
   Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–3774.
   Google Scholar
• Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 2012;118(22):5614–5622.
   Google Scholar
• Tofthagen C, Donovan KA, Morgan MA, et al. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21(12):3307–3313.
   Google Scholar
• Ezendam NP, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–517.
   Google Scholar
• ArgyriouAAIzquierdo C, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst. 2014;19(4):299–306.
   Google Scholar
• Kokotis P, Schmelz M, Kostouros E, et al. Oxaliplatin-Induced Neuropathy: a long-term clinical and neurophysiologic follow-up study. Clin Colorectal Cancer. 2016;15(3):e133–40.
   Google Scholar
• Kandula T, Farrar MA, Cohn RJ, et al. Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological, functional, and patient-reported outcomes. JAMA Neurol. 2018;75(8):980–988.
   Google Scholar
• Vissers PA, Mols F, Thong MS, et al. The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry. J Cancer Surviv. 2015;9(3):523–531.
   Google Scholar
• Briani C, Argyriou AA, Izquierdo C, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst. 2014;19(4):299–306.
   Google Scholar
• Bennett BK, Park SB, Lin CS-Y, et al. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012;20(11):2959–2967.
   Google Scholar
• Padman S, Lee J, Kumar R, et al. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)–cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer. 2015;23(3):861–869.
   Google Scholar
• André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116.
   Google Scholar
• Ness KK, Jones KE, Smith WA, et al. Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch Phys Med Rehabil. 2013;94(8):1451–1457.
   Google Scholar
• Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003;60(2):337–340.
   Google Scholar
• Johnson C, Pankratz VS, Velazquez AI, et al. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci. 2015;349(1–2):124–128.
   Google Scholar
• Martino MA, Miller E, Grendys EC. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. Gynecol Oncol. 2005;97(2):710–712.
   Google Scholar
• Terrazzino S, Argyriou AA, Cargnin S, et al. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. J Peripher Nerv Syst. 2015;20(1):15–23.
   Google Scholar
• Argyriou AA, Bruna J, Genazzani AA, et al. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017;13(8):492–504.
   Google Scholar
• Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12(12):1151–1161.
   Google Scholar
• Frigeni B, Cacciavillani M, Ermani M, et al. Neurophysiological examination of dorsal sural nerve. Muscle Nerve. 2012;46(6):895–898.
   Google Scholar
• Alberti P, Rossi E, Argyriou AA, et al. Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. Support Care Cancer. 2018;26(9):3143–3151.
   Google Scholar
• Mariotto S, Farinazzo A, Magliozzi R, et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 2018;23(3):174–177.
   Google Scholar
• Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518–e24.
   Google Scholar
• Meregalli C, Fumagalli G, Alberti P, et al. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol. 2018;307:129–132.
   Google Scholar
• Chambers SM, Qi Y, Mica Y, et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol. 2012;30(7):715–720.
   Google Scholar
• Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016;17(3):170–182.
   Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–1967.
   Google Scholar
• Albers J, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2007;1:CD005228:1-29.
   Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228:1-97.
   Google Scholar
• Kanat O, Ertas H, Caner B. Platinum-induced neurotoxicity: A review of possible mechanisms. World J Clin Oncol. 2017;8(4):329–335.
   Google Scholar
• Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.
   Google Scholar
• McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8(1):10–16.
   Google Scholar
• Jimenez-Andrade JM, Herrera MB, Ghilardi JR, et al. Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. Mol Pain. 2008;4:10.
   Google Scholar
• Sprowl JA, Ciarimboli G, Lancaster CS, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013;110(27):11199–11204.
   Google Scholar
• Ciarimboli G. Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo). 2012;2012:473829.
   Google Scholar
• Cavaletti G, Ceresa C, Nicolini G, et al. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity. Anticancer Res. 2014;34(1):483–486.
   Google Scholar
• Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci. 2007;27(35):9451–9457.
   Google Scholar
• Yan F, Liu JJ, Ip V, et al. Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity. J Neurochem. 2015;135(6):1099–1112.
   Google Scholar
• Marguerat S, Bähler J. Coordinating genome expression with cell size. Trends Genet. 2012;28(11):560–565.
   Google Scholar
• McDonald ES, Randon KR, Knight A, et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005;18(2):305–313.
   Google Scholar
• Alaedini A, Xiang Z, Kim H, et al. Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Exp Neurol. 2008;210(2):368–374.
   Google Scholar
• Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001;37(18):2457–2463.
   Google Scholar
• Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998;101(12):2842–2850.
   Google Scholar
• Podratz JL, Knight AM, Ta LE, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis. 2011;41(3):661–668.
   Google Scholar
• Podratz JL, Lee H, Knorr P, et al. Cisplatin induces mitochondrial deficits in Drosophila larval segmental nerve. Neurobiol Dis. 2017;97(Pt A):60–69.
   Google Scholar
• Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol. 2007;26(1):5–10.
   Google Scholar
• Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406(1):25–32.
   Google Scholar
• Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85(5):2293–2297.
   Google Scholar
• Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005;146(7):1027–1039.
   Google Scholar
• Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012;109(17):6704–6709.
   Google Scholar
• Deuis JR, Zimmermann K, Romanovsky AA, et al. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain. 2013;154(9):1749–1757.
   Google Scholar
• Wu SN, Chen BS, Wu YH, et al. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. Neurotoxicology. 2009;30(4):677–685.
   Google Scholar
• Benoit E, Brienza S, Dubois JM. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys. 2006;25(3):263–276.
   Google Scholar
• Kagiava A, Tsingotjidou A, Emmanouilides C, et al. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology. 2008;29(6):1100–1106.
   Google Scholar
• Descoeur J, Pereira V, Pizzoccaro A, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011;3(5):266–278.
   Google Scholar
• Dimitrov AG, Dimitrova NA. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. Muscle Nerve. 2012;45(3):403–411.
   Google Scholar
• Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve. 1998;21(2):137–158.
   Google Scholar
• Park SB, Lin CS, Kiernan MC. Nerve excitability assessment in chemotherapy-induced neurotoxicity. J Vis Exp. 2012 62.
   Google Scholar
• Krishnan AV, Lin CS, Park SB, et al. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol. 2009;89(3):288–313.
   Google Scholar
• Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32(1):51–60.
   Google Scholar
• Park SB, Lin CS, Krishnan AV, et al. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One. 2011;6(4):e18469.
   Google Scholar
• Argyriou AA, Cavaletti G, Antonacopoulou A, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013;119(19):3570–3577.
   Google Scholar
• Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009;132(Pt 10):2712–2723.
   Google Scholar
• Persson AK, Hoeijmakers JGJ, Estacion M, et al. Sodium channels, mitochondria, and axonal degeneration in peripheral neuropathy. Trends Mol Med. 2016;22(5):377–390.
   Google Scholar
• Marmiroli P, Cavaletti G, Carozzi V, et al. Calcium-related neurotoxicity of oxaliplatin: understanding the mechanisms to drive therapy. Curr Med Chem. 2015;22(32):3682–3694.
   Google Scholar
• Alberti P. Chemotherapy-induced peripheral neurotoxicity - outcome measures: the issue. Expert Opin Drug Metab Toxicol. 2017;13(3):241–243.
   Google Scholar
• Carozzi VA, Chiorazzi A, Canta A, et al. Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: new useful ready-to-use animal models. Exp Neurol. 2015;264:92–102.
   Google Scholar
• Cavaletti G, Petruccioli MG, Marmiroli P, et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res. 2002;22(6C):4199–4204.
   Google Scholar
• Verdú E, Vilches JJ, Rodríguez FJ, et al. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve. 1999;22(3):329–340.
   Google Scholar
• Mimura Y, Kato H, Eguchi K, et al. Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology. 2000;21(4):513–520.
   Google Scholar
• Bruna J, Udina E, Alé A, et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol. 2010;223(2):599–608.
   Google Scholar
• Meregalli C, Carozzi VA, Sala B, et al. Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice. J Biol Regul Homeost Agents. 2015;29(1):115–124.
   Google Scholar